[1]
|
Johnson, D.B., Peng, C. and Sosman, J.A. (2015) Nivolumab in Melanoma: Latest Evidence and Clinical Potential. Therapeutic Ad-vances in Medical Oncology, 7, 97-106. https://doi.org/10.1177/1758834014567469
|
[2]
|
Kalinsky, K. and Hershman, D.L. (2012) Cracking Open Window of Opportunity Trials. Journal of Clinical Oncology, 30, 2573-2575. https://doi.org/10.1200/JCO.2012.42.3293
|
[3]
|
Bae, S.B., Cho, H.D., Oh, M.H., Lee, J.H., Jang, S.H., Hong, S.A., et al. (2016) Expression of Programmed Death receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. Journal of Breast Cancer, 19, 242. https://doi.org/10.4048/jbc.2016.19.3.242
|
[4]
|
Adams, S., Gray, R.J., Demaria, S., Goldstein, L., Perez, E.A., Shulman, L.N., et al. (2014) Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers from Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 32, 2959. https://doi.org/10.1200/JCO.2013.55.0491
|
[5]
|
Ono, M., Tsuda, H., Shimizu, C., Yamamoto, S., Shibata, T., Yamamoto, H., et al. (2012) Tumor-Infiltrating Lymphocytes Are Correlated with Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Breast Cancer Research & Treatment, 132, 793-805. https://doi.org/10.1007/s10549-011-1554-7
|
[6]
|
Luen, S. J., Salgado, R., Fox, S., Savas, P., Engwong, J., Clark, E., et al. (2017) Tumour-Infiltrating Lymphocytes in Advanced HER2-Positive Breast Cancer Treated with Pertuzumab or Placebo in Addition to Trastuzumab and Docetaxel: A Retrospective Analysis of the CLEOPATRA Study. Lancet Oncology, 18, 52-62.
https://doi.org/10.1016/S1470-2045(16)30631-3
|
[7]
|
Tung, N.M. and Winer, E.P. (2015) Tumor-Infiltrating Lymphocytes and Response To platinum in Triple-Negative Breast Cancer. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 33, 969-971. https://doi.org/10.1200/JCO.2014.59.6031
|
[8]
|
Dong, H., Zhu, G., Tamada, K. and Chen, L. (1999) B7-h1, a Third Member of the B7 Family, Co-Stimulates T-Cell Proliferation and Interleukin-10 Secretion. Nature Medicine, 5, 1365-1369. https://doi.org/10.1038/70932
|
[9]
|
Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. (2002) Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. Journal of Experimental Medicine, 192, 1027. https://doi.org/10.1084/jem.192.7.1027
|
[10]
|
Bourjordan, H., Esensten, J.H., Martinezllordella, M., Penaranda, C., Stumpf, M. and Bluestone, J.A. (2011) Intrinsic and Extrinsic Control of Peripheral T-Cell Tolerance by Costimulatory Molecules of the CD28/ B7 Family. Immunological Reviews, 241, 180-205. https://doi.org/10.1111/j.1600-065X.2011.01011.x
|
[11]
|
Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. (2008) Pd-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677. https://doi.org/10.1146/annurev.immunol.26.021607.090331
|
[12]
|
Gajewski, T.F., Schreiber, H. and Fu, Y.X. (2013) Innate and Adaptive Immune Cells in the Tumor Microenvironment. Nature Immunology, 14, 1014-1022. https://doi.org/10.1038/ni.2703
|
[13]
|
Soliman, H.H. (2017) Nab-Paclitaxel as a Potential Partner with Checkpoint Inhibitors in solid Tumors. Oncotargets & Therapy, 10, 101-112. https://doi.org/10.2147/OTT.S122974
|
[14]
|
Chen, D. and Mellman, I. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39, 1.
https://doi.org/10.1016/j.immuni.2013.07.012
|
[15]
|
Woo, S.R., Corrales, L. and Gajewski, T.F. (2015) The Sting Pathway and the T Cell-Inflamed Tumor Microenvironment. Trends in Immunology, 36, 250. https://doi.org/10.1016/j.it.2015.02.003
|
[16]
|
Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135. https://doi.org/10.1056/NEJMoa1504627
|
[17]
|
Brahmer, J.R., Hammers, H. and Lipson, E.J. (2015) Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity. Future Oncology, 11, 1307-1326. https://doi.org/10.2217/fon.15.52
|
[18]
|
Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. https://doi.org/10.1038/nature21349
|
[19]
|
Cimino-Mathews, A., Thompson, E., Taube, J.M., Ye, X., Yao, L., Meeker, A., et al. (2016) PD-L1 (B7-H1) Expression and the Immune Tumor Microenvironment in Primary and Metastatic Breast Carcinomas. Human Pathology, 47, 52-63.
https://doi.org/10.1016/j.humpath.2015.09.003
|
[20]
|
Burstein, M.D., Tsimelzon, A., Poage, G.M., Covington, K.R., Contreras, A., Fuqua, S.A., et al. (2015) Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 21, 1688-1698.
https://doi.org/10.1158/1078-0432.CCR-14-0432
|
[21]
|
Stagg, J. and Allison, J.P. (2011) Anti-ErbB-2 mAb Therapy Requires Type I and II Interferons and Synergizes with Anti-PD-1 or Anti-CD137 mAb Therapy. Proceedings of the National Academy of Sciences of the United States of America, 108, 7142-7147. https://doi.org/10.1073/pnas.1016569108
|
[22]
|
Nanda, R., Chow, L.Q., Dees, E.C., Berger, R., Gupta, S., Geva, R., et al. (2016) Pembrolizumab in Patients with Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34, 2460-2467. https://doi.org/10.1200/JCO.2015.64.8931
|
[23]
|
Schmid, P., Cruz, C., Braiteh, F.S., Eder, J.P., Tolaney, S., Kuter, I., et al. (2017) Abstract 2986: Atezolizumab in Metastatic TNBC (mTNBC): Long-Term Clinical Outcomes and Biomarker Analyses. Cancer Research, 77, 2986-2986.
https://doi.org/10.1158/1538-7445.AM2017-2986
|
[24]
|
Ghiringhelli, F., Menard, C., Puig, P.E., Ladoire, S., Roux, S., Martin, F., et al. (2007) Metronomic Cyclophosphamide Regimen Selectively Depletes CD4+ CD25+ Regulatory T Cells and Restores T and NK Effector Functions in End Stage Cancer Patients. Cancer Immunology Immunotherapy, 56, 641-648. https://doi.org/10.1007/s00262-006-0225-8
|
[25]
|
Zitvogel, L., Galluzzi, L., Smyth, M.J. and Kroemer, G. (2013) Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. Immunity, 39, 74-88.
https://doi.org/10.1016/j.immuni.2013.06.014
|
[26]
|
Bracci, L., Schiavoni, G., Sistigu, A. and Belardelli, F. (2014) Immune-Based Mechanisms of Cytotoxic Chemotherapy: Implications for the Design of Novel and Rationale-Based Combined Treatments against Cancer. Cell Death & Differentiation, 21, 15-25. https://doi.org/10.1038/cdd.2013.67
|
[27]
|
Adams, S., Diamond, J., Hamilton, E., Pohlmann, P., Tolaney, S., Molinero, L., et al. (2016) Abstract P2-11-06: Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer. Cancer Research, 76, P2-11-06-P2-11-06.
https://doi.org/10.1158/1538-7445.SABCS15-P2-11-06
|